These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27825812)

  • 21. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.
    Davidson B; Nymoen DA; Elgaaen BV; Staff AC; Tropé CG; Kærn J; Reich R; Falkenthal TE
    Virchows Arch; 2014 Jun; 464(6):701-7. PubMed ID: 24756216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
    Vaksman O; Davidson B; Tropé C; Reich R
    Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
    Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
    Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.
    Brunetti M; Holth A; Panagopoulos I; Staff AC; Micci F; Davidson B
    Virchows Arch; 2019 Feb; 474(2):177-185. PubMed ID: 30467600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2021 Mar; 32(2):161-168. PubMed ID: 33025675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exosome-derived miRNAs and ovarian carcinoma progression.
    Vaksman O; Tropé C; Davidson B; Reich R
    Carcinogenesis; 2014 Sep; 35(9):2113-20. PubMed ID: 24925027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.
    Bunkholt Elstrand M; Dong HP; Ødegaard E; Holth A; Elloul S; Reich R; Tropé CG; Davidson B
    Hum Pathol; 2010 Jun; 41(6):794-804. PubMed ID: 20153512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
    Davidson B; Doutel D; Holth A; Nymoen DA
    Virchows Arch; 2023 Jun; 482(6):975-982. PubMed ID: 37067588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
    Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
    Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
    Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
    Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
    Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
    Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
    Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    Ritterhouse LL; Nowak JA; Strickland KC; Garcia EP; Jia Y; Lindeman NI; Macconaill LE; Konstantinopoulos PA; Matulonis UA; Liu J; Berkowitz RS; Nucci MR; Crum CP; Sholl LM; Howitt BE
    Mod Pathol; 2016 Aug; 29(8):893-903. PubMed ID: 27150160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.
    Hetland TE; Nymoen DA; Emilsen E; Kærn J; Tropé CG; Flørenes VA; Davidson B
    Gynecol Oncol; 2012 Sep; 126(3):460-5. PubMed ID: 22652154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.
    Tuft Stavnes H; Nymoen DA; Hetland Falkenthal TE; Kærn J; Tropé CG; Davidson B
    Am J Clin Pathol; 2014 Jul; 142(1):51-7. PubMed ID: 24926085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.